We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mereo BioPharma Group PLC | NASDAQ:MREO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.15 | 3.25 | 3.42 | 0 | 12:03:04 |
From May 2021 to May 2024
By Colin Kellaher
Mereo BioPharma Group PLC on Tuesday said the U.S. Food and Drug Administration granted orphan-drug designation to alvelestat for the treatment of alpha-1 antitrypsin deficiency, an genetic disorder that could cause lung disease and liver disease.
The London clinical-stage biopharmaceutical company said it developing alvelestat for the treatment of lung disease associated with the disorder, with a Phase 2 proof-of-concept clinical trial underway.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing-exclusivity period against competition.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 26, 2021 08:42 ET (12:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Mereo BioPharma Chart |
1 Month Mereo BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
